Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulvestrant + imiquimod
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intramuscular, Topical
01
Overview
Fulvestrant + imiquimod is a combination therapy approach being investigated for breast cancer treatment, particularly for cases with cutaneous metastasis. Fulvestrant is an estrogen receptor antagonist that blocks estrogen effects in the body, limiting tumor growth in hormone receptor-positive breast cancers. Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist, stimulating innate and acquired immune responses against cancer cells. The combination may provide synergistic effects by combining hormonal therapy with immunomodulation.
02
Targets
ESR1 (ERα)ESR2 (ERβ)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on fulvestrant + imiquimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulvestrant + imiquimod.